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Abstract Although acromegaly is a rare disease, the
clinical, economic and health-related quality of life
(HRQoL) burden is considerable due to the broad spectrum
of comorbidities as well as the need for lifelong manage-
ment. We performed a comprehensive literature review of
the past 12 years (1998–2010) to determine the beneﬁt of
disease control (deﬁned as a growth hormone [GH] con-
centration\2.5 lg/l and insulin-like growth factor [IGF]-1
normal for age) on clinical, HRQoL, and economic out-
comes. Increased GH and IGF-1 levels and low frequency
of somatostatin analogue use directly predicted increased
mortality risk. Clinical outcome measures that may
improve with disease control include joint articular carti-
lage thickness, vertebral fractures, left ventricular function,
exercise capacity and endurance, lipid proﬁle, and
obstructive apnea events. Some evidence suggests an
association between controlled disease and improved
HRQoL. Total direct treatment costs were higher for
patients with uncontrolled compared to controlled disease.
Costs incurred for management of comorbidities, and
indirect cost could further add to treatment costs. Opti-
mizing disease control in patients with acromegaly appears
to improve outcomes. Future studies need to evaluate
clinical outcomes, as well as HRQoL and comprehensive
economic outcomes achieved with controlled disease.
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Introduction
Acromegaly is a chronic, debilitating disorder caused by
excessive growth hormone (GH) production predominantly
due to a benign pituitary adenoma [1]. The overall annual
incidence of acromegaly is approximately 3.3 cases/mil-
lion, with a prevalence of 58–130 cases/million people
[2, 3]. Diagnosing acromegaly is hampered by several
factors, including the slow, insidious onset of the disease,
and variability of biochemical assays beset by inappropri-
ate reference ranges and conversion factors for GH and
insulin-like growth factor (IGF)-1 laboratory tests. Reports
in the literature suggest that the mean time from symptom
onset to diagnosis is 3–7 years [4, 5].
Treatment options for patients with acromegaly include
surgery, radiotherapy, and pharmacologic therapies. A
cost-effective treatment strategy appears to be ﬁrst-line
surgery followed when needed by second-line octreotide
LAR [6]. The goals of treatment are to achieve disease
control, while minimizing adverse effects [1]. Disease
control for this paper is deﬁned as a GH concentration less
than 2.5 lg/l and a normal, age-adjusted IGF-1 level. Many
studies report outcomes for patients not achieving disease
control using this deﬁnition. Therefore, comparison of
study results is difﬁcult.
Unfortunately, disease control is elusive for many
patients with acromegaly. Data from registry studies show
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(Table 1). Speciﬁcally, less than 50% of patients in these
registry studies achieved disease control [7–9]. Two of
these studies exclusively assessed patients treated with
medical therapy. In these two studies, only 7 and 24% of
patients achieved disease control with primary medical
therapy and up to 42% with secondary medical therapy
[8, 9].
In these registry studies, patients treated with radio-
therapy either alone or with surgery or medical therapy
were most likely to achieve disease control [8, 9]. How-
ever, the disadvantages of radiotherapy must be considered
when evaluating these results. These include a lag time to
response ([6 years in most patients), the development of
hypopituitarism in over 50% of patients, and the risk of
cerebrovascular events/stroke (21% at 20 years) and sec-
ondary brain tumors (2% at 20 years) [10–13].
In general, study results suggest an improvement in
several outcomes in patients who lower their GH and/or
IGF-1 concentrations with treatment compared to baseline.
Less clear is the impact of disease control on health-related
quality of life (HRQoL) and economic outcomes. A clear
understanding of the potential beneﬁts of disease control,
and how this may translate into policy, reimbursement, and
clinical decision-making, could improve outcomes for
patients with acromegaly. Therefore, we conducted a study
to determine the clinical, HRQoL, and economic beneﬁts
of achieving disease control in patients with acromegaly.
To our knowledge, this is the ﬁrst attempt to systematically
review the impact of disease control deﬁned as both a
GH\2.5 lg/l and normal age-adjusted IGF-1 levels on
these outcomes. We sought to answer the following ques-
tions: Do patients with controlled disease live longer than
patients with uncontrolled disease? Are comorbidities
decreased in patients with controlled compared to uncon-
trolled disease? Is HRQoL improved in patients with
controlled compared to uncontrolled disease? Finally, is
there an economic beneﬁt associated with disease control?
Methods
A comprehensive literature review of the past 12 years
(1998–2010) was conducted in MEDLINE, EMBASE,
Econlit, and PsychInfo using the search terms acromegaly
AND epidemiology, morbidity, mortality, complications,
long-term outcomes, costs, economics, QoL, and utilities.
Additional searches were conducted to identify clinical
trials that evaluated somatostatin analogue, dopamine
agonist, or pegvisomant administration on disease control
and outcomes. Additional abstracts were identiﬁed
through article bibliographies and searches in conference
proceedings (2003–2009). Prospective or retrospective and
cross-sectional studies or meta-analyses that reported on
the relationship of comorbidity, long-term outcomes, eco-
nomic factors, or HRQoL and disease control in adults with
acromegaly were retained. Figure 1 summarizes the liter-
ature review selection process.
Table 1 Percentage of patients achieving disease control in open, uncontrolled registry studies with various treatment strategies
Treatment Bex et al. (2007) [8]
Belgium and Luxembourg
Petersenn et al. (2008) [7]
Germany
Mestron et al. (2004) [9]
Spain
b
n Normal
IGF-I
(%)
GH\2 lg/l
(%)
Controlled
(%)
n Normal
IGF-I
(%)
GH\2.5 lg/l
(%)
n Controlled
(%)
Active
disease
(%)
Surgery 125 36 36 34 554 54.3 67.3 246 46.3 19.5
Radiotherapy 20 50 70 50 NR NR 29 34.5 44.8
Primary medical therapy 74 31 51 24 113
a 7.1 92.9
SSA 57
c NR NR 28 145 36.3 30.5
Dopamine agonist 15 NR NR 13 NR NR
Secondary medical therapy 121 53 59 42
Surgery 65 52 56 37 277 35.7 64.3
Radiotherapy 4 25 25 0 NR NR 42 11.9 88.1
Surgery ? radiotherapy 52 59 65 52 NR NR 359 27.3 72.4
SSA followed by surgery 93 62.9 68.4
Surgery followed by SSA 34 24.1 45.5
GH growth hormone, IGF-1 insulin-like growth factor-1, NR not reported, SSA somatostatin analogue
a 68.3% of patients treated with SSA; 31.4% treated with dopamine agonists;
bPercentages may not add up to 100% due to missing data;
cTwo patients received dopamine agonists in conjunction with SSA
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Do patients with controlled disease live longer?
Overall, mortality is increased in patients with acromegaly
[14–22] (Fig. 2;[ 23, 24]). Results from two meta-analyses
suggest that disease control is inversely related to mortal-
ity; as disease control improves mortality decreases [23,
24]. Factors found to decrease mortality included disease
remission, decreased GH concentrations, normalized IGF-1
concentrations, and increased somatostatin analogue use
(Table 2)[ 23]. These studies also suggest that achieving
disease control has the potential to essentially normalize
mortality in the acromegaly patient to that of the general
population [24].
One exception may be when radiotherapy is included as
part of treatment. The meta-analysis by Dekkers et al.
found higher mortality in studies before 1995 when
patients were more likely to receive radiotherapy as pri-
mary treatment [24]. Similarly, Sherlock et al. found a
2-fold increase in mortality in acromegaly patients treated
with radiotherapy compared with the general population
(SMR 2.1; 95% CI, 1.7–2.6; P = 0.006) [25]. Speciﬁcally,
in patients who received radiotherapy, there was a signif-
icantly higher increase in the risk of cerebrovascular deaths
(SMR 4.1; 95% CI, 2.3–6.6; P = 0.034) [25].
Are comorbidities decreased with controlled disease?
Many patients with acromegaly have untreated disease for
several years prior to diagnosis and a spectrum of mor-
bidities are apparent. In one study, 40% of patients at
diagnosis had multiple comorbidities [4]. Some, but not all,
of these comorbidities can be reversed upon cure or control
of the patient’s condition [2]. Results from several studies
show signiﬁcant improvements in a number of key acro-
megaly comorbidities when disease control is achieved
(Table 3).
Glucose metabolism
Altered glucose metabolism in patients with acromegaly
varies from impaired glucose tolerance (16–46% of
patients) to overt diabetes mellitus (19–56% of patients)
[26]. Glucose-related metabolic abnormalities can be
reversed in patients with acromegaly when GH and IGF-1
concentrations are controlled by either surgery or admin-
istration of pharmacologic therapy [33]. Surgery improves
glucose tolerance and pegvisomant appears to improve
insulin sensitivity and carbohydrate metabolism [26].
417 potentially relevant
publications identified and
screened for retrieval
168 full-text articles retrieved for
detailed review
(109 clinical, 37 economics, 22 quality of life)
110 studies deemed likely to be
relevant for inclusion in the review:
￿  Epidemiology (incl. meta-analyses
 of morbidity and mortality): 13
￿  Cardiovascular and other 
 long-term outcomes: 19
￿  Clinical studies of medical
 therapies, including somatostatin
 analogues, related to morbidity and
 mortality, etc: 48
￿  Economic: 8
￿  Quality of life: 22
58 publications excluded due to:
￿  Only focusing on surgery or 
 radiotherapy
￿  General review only
￿  Clinical trial efficacy studies not 
  reporting morbidity relationships
  to biochemical control
￿  Only mentions drug price
￿  Only mentions economic burden
  or costs in discussion or intro, but
  no formal analysis
￿  Clinical trial studies not reporting
  resource use or economic data
249 publications excluded based on
title and abstract
(including case report articles,
non-English languages)
Fig. 1 Flow diagram for study selection
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Fig. 2 Acromegaly and
mortality: observed deaths in
acromegaly versus expected
deaths in general population
[23, 24]
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insulin resistance induced by elevated GH levels [26], and
may reduce insulin needs in overt diabetes. However,
somatostatin therapy may also decrease islet cell insulin
secretion thereby worsening glucose-related metabolic
abnormalities [34]. Nevertheless, in most patients, these
effects counterbalance each other and patients maintain an
euglycemic state.
Cardiovascular effects/hypertension
The hallmark cardiac effect in patients with acromegaly is
concentric biventricular hypertrophy due to thickened
cardiac walls [26]. Cardiac hypertrophy can occur in
patients with acromegaly in the absence of hypertension
but is further aggravated by hypertension and glucose
abnormalities [26]. In fact, the most important factor in the
development of acromegalic cardiac hypertrophy is arterial
hypertension [35]. Other cardiovascular effects that occur
in patients with acromegaly include arrhythmias such as
ectopic beats, paroxysmal atrial ﬁbrillation, paroxysmal
supraventricular tachycardia, sick sinus syndrome, ven-
tricular tachycardia, and bundle branch block, and cardiac
valve disease [36].
Treatment of acromegaly can slow cardiac disease
progression and ultimately decrease cardiovascular mor-
bidity and mortality [26]. Data from numerous studies
show decreased left ventricular hypertrophy [30, 37–41],
improvement in diastolic function [30, 37, 39–43], no
change or improved systolic function [30, 37, 39–43],
decreased heart rate [30, 38, 43], and decreased arrhyth-
mias [41] following treatment with a somatostatin ana-
logue. Table 4 highlights cardiac function endpoints from
one study as an example of what might be achieved with
disease control in patients with acromegaly [29].
Furthermore, in terms of impact on hypertension, acro-
megaly patients with controlled disease (deﬁned as a nor-
mal IGF-1 concentration) have shown lower systolic
(P = 0.04) and diastolic (P = 0.002) blood pressure val-
ues compared to those with uncontrolled disease [44].
Skeletal system complications
The most frequent complaint by patients with acromegaly
is arthropathy [26]; up to 70% of patients with acromegaly
have acral complications at diagnosis. It is currently
unknown whether GH and IGF-1 control can reverse
arthropathy in patients with acromegaly, however,
improvement in signs and symptoms was demonstrated
[45, 46]. Improvements observed with disease control
include decreased carpal tunnel syndrome and a reduction
in joint space thickness, as measured by articular cartilage
thickness via ultrasound [26, 31, 47, 48] (Fig. 3)[ 31].
Vertebral fractures also appear to be decreased in
patients with controlled compared to uncontrolled disease
[32]. In this study, patients with controlled disease had a
33% fracture rate compared with an 80% fracture rate in
patients with uncontrolled disease. In fact, patients with
uncontrolled acromegaly experienced fractures even with
normal bone mineral density, suggesting that normal bone
mineral density is not protective against vertebral fractures
in patients with uncontrolled disease. Patients with con-
trolled disease had a 2.4-fold lower fracture rate compared
with uncontrolled disease (P\0.008).
Sleep apnea
Sleep apnea syndrome is deﬁned as the presence of 5–10
sleep apnea episodes or hypopneas of at least 10 seconds
duration/hour of nocturnal sleep [49]. Patients with acro-
megaly can have central, obstructive, or mixed sleep apnea,
with obstructive sleep apnea being the most common form.
Results of some studies suggest an improvement in sleep
apnea in patients achieving disease control [26, 28, 33]. In
a small cross-sectional study, Davi et al. found that a higher
proportion of patients with uncontrolled compared to
controlled disease had obstructive sleep apnea (55 and
39%, respectively) [28]. Additionally, the average number
of obstructive apnea events/hour was roughly 4 times
higher among those with uncontrolled disease. Somato-
statin analogue administration may be beneﬁcial in some
patients, particularly those with mixed or central sleep
apnea [26].
Lipid metabolism
Achievement of disease control and treatment with
somatostatin analogue therapy appears to have beneﬁcial
Table 2 Inﬂuence of disease control and somatostatin analogue use
on mortality in patients with acromegaly [23]
Acromegaly population SMR
(95% CI)
Risk ratio
(P value)
Remission in[70% of patients 1.2 (1.0–1.5) 1.7 (\0.05)
Remission in\70% of patients 2.0 (1.6–2.3)
GH\2.5 lg/l 1.1 (0.9–1.4) 1.7 (\0.05)
GH[2.5 lg/l 1.9 (1.5–2.4)
Normal IGF-I 1.1 (0.9–1.4) 2.3 (\0.05)
Increased IGF-I 2.5 (1.6–4.0)
Somatostatin analogue use
in[30% patients
1.2 (1.0–1.5) 1.7 (\0.001)
Somatostatin analogue use
in\30% of patients
2.0 (1.6–2.3)
CI conﬁdence interval, GH growth hormone, IGF-1 insulin-like
growth factor-1, SMR standardized mortality ratio
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123effects on lipid metabolism, with studies reporting signif-
icant decreases in total cholesterol, low-density lipoprotein
(LDL) cholesterol, and triglyceride levels and increases in
high-density lipoprotein (HDL) associated with octreotide
therapy [38, 50, 51]. Similar results are reported following
treatment with lanreotide [52]. In a study designed to
determine the affect of disease control on lipid metabolism,
patients with controlled versus uncontrolled acromeg-
aly had signiﬁcantly lower triglycerides (153.1 ± 64.5
vs. 223.4 ± 107.4 mg/dl; P\0.001), very low-density
Table 3 Impact of disease control (GH\2.5 lg/l and IGF-1 normal for age) on morbidity in patients with acromegaly
Complication Prevalence in
acromegaly
[8, 9, 26] (%)
Study description Improvement with disease control
Lipid abnormalities 26 Vilar et al. (2007) [27] Metabolic proﬁle
study N = 98; 12 controlled,
50 uncontrolled, 36 healthy
controls
Controlled versus uncontrolled
11% decrease in LDL (P = 0.01)
31% decrease in triglycerides (P\0.001)
61% decrease in VLDL (P\0.001)
70% decrease in Lp(a) (P = 0.023)
53% decrease in HOMA-IR (P = 0.032)
Sleep apnea 13–80 Davi et al. (2008) [28] Sleep apnea
syndrome in acromegaly patients
N = 36, 18 controlled disease;
18 uncontrolled/active disease
Prevalence of sleep apnea
Controlled 39%
Uncontrolled 56%
Controlled versus uncontrolled
*4-fold decrease in obstructive apnea events/hour
*2-fold decrease in apnea/hypopnea index
Cardiovascular disease 14–18 Van Thiel et al. (2005) [29] LV function
study in active versus inactive disease
N = 39; 14 controlled, 8 cured,
17 uncontrolled disease
Controlled versus uncontrolled (P\0.05 for all
comparisons)
30% decrease in inter-ventricular septum diameter
36% decrease in left ventricular mass
35% decrease in left ventricular mass index
23% increase in fractional shortening
21% increase in ejection fraction
Colao et al. (2000) [30] LV structure and
performance study in somatostatin
analogue-naı ¨ve patients with testing
3- and 6-months after octreotide LAR
N = 15, 9 controlled, 6 uncontrolled
Controlled
a
21% decrease in left ventricular mass index
(P B 0.001)
13% increase in ejection fraction at rest (P = 0.005)
17% increase in ejection fraction at peak exercise
(P = 0.002)
30% increase in exercise duration (P = 0.01)
16% increase in exercise capacity (P = 0.05)
Arthropathy 20–70 Colao et al. (2003) [31] Joint thickness
study of de novo acromegaly patients
following 12 months of octreotide LAR
N = 90; 30 de novo patients, 30 cured
patients; 30 healthy controls
Well-controlled patients normalized joint thickness
61% at shoulder, 89% at right knee
Maximum decrease in joint thickness after 12
months of long-acting octreotide treatment
Uncontrolled 5–8% across all joint sites
Controlled 25–29% across all joint sites
Spinal involvement 40–50 Bonadonna et al. (2005) [32] Vertebral
fractures in postmenopausal women
with acromegaly N = 72; 21 controlled,
15 uncontrolled, 36 postmenopausal
controls
Controlled 33% fracture rate (only in patients with
low bone mineral density)
Uncontrolled 80% fracture rate (even with normal
bone mineral density)
Postmenopausal controls 31% fracture rate
2.4-fold decrease in signiﬁcant events (P\0.008)
GH growth hormone, HOMA-IR homeostasis model assessment of insulin resistance, IGF-1 insulin-like growth factor-1, LDL low-density
lipoprotein, Lp(a) lipoprotein (a), LV left ventricular, VLDL very low-density lipoprotein
a Patients controlled following 6 months of long-acting octreotide treatment, comparison made between baseline and 6 months laboratory values
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22.2 mg/dl; P\0.001), and lipoprotein (a) (25.5 ± 15.8
vs. 85.1 ± 56.1 mg/dl; P = 0.023) and signiﬁcantly higher
HDL cholesterol (45.3 ± 14.0 vs. 44.6 ± 9.9 mg/dl;
P\0.001) concentrations [27].
Is HRQoL improved with controlled disease?
Four published studies compared HRQoL in patients with
controlled and uncontrolled acromegaly using the Acro-
QoL instrument [53–56]. The AcroQoL is a disease-spe-
ciﬁc questionnaire designed to evaluate HRQoL in patients
with acromegaly (Table 5)[ 57]. A signiﬁcant difference
between AcroQoL scores in controlled and uncontrolled
patients was found only in the study by Trepp et al. [54].
This was the smallest of the four studies, enrolling only 33
patients with acromegaly; 21 patients (64%) were classiﬁed
as being in remission (random GH value or a nadir GH
value following an oral glucose tolerance test [OGTT]
\1 lg/l and normal IGF-1 levels), six patients (18%) as
having active disease, and the remaining six patients (18%)
as having discordant results. Patients with active disease
Table 4 Improvement in cardiac function with disease control [29]
Variable Untreated Uncontrolled Well controlled Cured
IVSD (mm) 13.1 ± 1.6 13.8 ± 1.1 9.6 ± 0.5
a,b 10.6 ± 1.3
LVM (g) 250 ± 48 314 ± 57 201 ± 20
b 199 ± 43
LVMI (g/m
2) 126.0 ± 22.5 153 ± 27.7 99.6 ± 9.5
b 100.3 ± 19.5
FS (%) 30.9 ± 2.5 29.9 ± 2.6 36.8 ± 1.7
b 37.4 ± 1.4
c
LVEF (%) 57.8 ± 3.8 59.7 ± 2.81 72.4 ± 2.6
a,b 73 ± 1.8
c,d
FS fractional shortening, IVSD inter-ventricular septum diameter, LVEF left ventricular ejection fraction, LVM left ventricular mass, LVMI LVM
index, LVM/body surface area
Adapted from van Thiel et al. [29].   Society of the European Journal of Endocrinology (2005). Reproduced by permission
a P\0.05 untreated versus well controlled;
bP\0.05 uncontrolled versus well controlled;
cP\0.05 uncontrolled versus cured;
dP\0.5
untreated versus cured
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Fig. 3 Comparison of joint articular cartilage thickness in patients
with controlled acromegaly, uncontrolled acromegaly, and no acro-
megaly. Adapted from Colao et al. [31].   European Society of
Endocrinology. Reproduced by permission
Table 5 The AcroQoL questionnaire [57]
Scale 1: Physical
My legs are weak
I get depressed
I have problems carrying out my usual activities
The illness affects my performance at work or in my usual tasks
My joints ache
I am usually tired
I feel like a sick person
I feel weak
Scale 2–1: Psychological/appearance
I feel ugly
I look awful in photographs
I look different in the mirror
Some parts of my body (nose, feet, hands…) are too big
I have problems doing things with my hands, for example, sewing
or handling tools
I snore at night
It is hard for me to articulate words due to the size of my tongue
Scale 2–2: Psychological/personal relations
I avoid going out very much with friends because of my appearance
I try to avoid socializing
I feel rejected by people because of my illness
People stare at me because of my appearance
I have problems with sexual relationships
The physical changes produced by my illness govern my life
I have little sexual appetite
Scales measured in frequency of occurrence (always, most of the
time, sometimes, rarely, never) or degree of agreement (completely
agree, moderately agree, neither agree nor disagree, moderately dis-
agree, completely disagree)
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and lower scores on the physical (P = 0.021) and psy-
chological scales (P = 0.023), and the personal relations
subscale (P = 0.042) suggesting improved HRQoL with
disease control.
Is there an economic beneﬁt with disease control?
Two studies compared the economic burden of controlled
and uncontrolled acromegaly [58, 59]. Both studies eval-
uated direct costs from the European perspective. No high-
quality studies were identiﬁed in the United States that
speciﬁcally assessed patient costs with controlled versus
uncontrolled disease.
Didoni et al. performed a cost-of-illness study assessing
health resource consumption due to acromegaly and asso-
ciated comorbidities [58]. This retrospective study evalu-
ated approximately 7 years of data obtained from 142
patients treated at two hospitals in northern Italy in the
Italian Healthcare Service. Direct costs analyzed included
those for hospitalizations, diagnostic and laboratory tests,
specialist visits, and drugs. Ninety-one patients had con-
trolled disease (GH following an OGTT\1 lg/l and
IGF-1 normal for age) and 43 patients had uncontrolled
disease (GH following an OGTT[1 lg/l and/or an
increased IGF-1 for age). Total annual costs were
approximately 1.6 times higher in patients with uncon-
trolled (€12,533) compared to controlled disease (€7,968).
Drug costs accounted for most of the cost differences
between the controlled and uncontrolled patients. Drug
costs were 1.74 times higher in patients with uncontrolled
versus controlled disease. Although the rate of overall
comorbidities was similar between the controlled and
uncontrolled groups, the rate of diabetes was 17% higher
and hypertension 44% higher in the uncontrolled than
controlled group. The economic value of reducing rates of
diabetes and hypertension could be substantial, as this
study suggests 60% higher costs related to these two
comorbidities in patients with uncontrolled acromegaly.
Luque-Ramı ´rez et al. determined costs for 11 acro-
megaly patients with invasive pituitary adenomas [59].
Data were analyzed for 4 years following diagnosis. Costs
were determined using data from the Centre for Health
Economics and Social Policy Studies and the Ofﬁcial
College of Pharmacists in Spain (year not speciﬁed). All
patients underwent transsphenoidal pituitary surgery; 10
patients also required medical therapy (somatostatin ana-
logue n = 6; bromocriptine n = 3; somatostatin analogue
plus bromocriptine n = 1); six patients also required
fractionated radiotherapy. A total of ﬁve patients had
controlled disease (GH\2 lg/l and an IGF-1 level normal
for age) and six patients had uncontrolled disease (ﬁve
patients had a GH[2 lg/l but normal IGF-I and one
patient had a GH\2 lg/l but an elevated IGF-I level).
The mean annual global cost/patient was €7,570. Interest-
ingly, in this study annual global treatment costs were
higher in patients with controlled disease (€9,874) versus
uncontrolled disease (€7,072). However, three patients
with uncontrolled disease received only bromocriptine, a
lower cost therapy than somatostatin analogues. Analysis
of somatostatin analogue therapy costs found higher
treatment costs in patients with uncontrolled compared to
controlled disease. Not surprisingly, annual treatment costs
were lowest for the patient cured with surgery alone
(€1,343).
Discussion
Disease burden is deﬁned as the impact of a health problem
measured by ﬁnancial cost, mortality, morbidity, or other
indicators [60]. The objective of this assessment was to
determine acromegaly disease burden as measured by
clinical, HRQoL, and economic outcomes. Results from
this critical literature review show that the clinical burden
of controlled and uncontrolled acromegaly is fairly well
deﬁned in terms of mortality. In comparison, the burden of
controlled and uncontrolled acromegaly in terms of mor-
bidity, HRQoL, and direct and indirect costs is less deﬁned.
Few studies assessed the impact of disease control on direct
medical care costs and HRQoL. No studies assessed the
impact of disease control on indirect costs such as work
productivity/employment.
A review of data from registry studies shows that the
majority of patients with acromegaly do not achieve dis-
ease control [7–9]. Results from this review document the
beneﬁts of controlled compared with uncontrolled disease.
Mortality, morbidity, and costs are all decreased in patients
with controlled compared to uncontrolled disease. The
effect of controlled disease on HRQoL is less clear. Results
from one study suggest improved HRQoL in patients with
controlled compared to uncontrolled disease [54]. Several
possibilities may explain why an association between
HRQoL and disease control is not evident. First, the
AcroQoL tool may not be sufﬁciently sensitive to detect
differences in HRQoL between controlled and uncontrolled
patients. Second, patients with acromegaly continue to
have cosmetic and orthopedic deformities because of the
lag time encountered to diagnosis, and in many cases these
are not reversed with treatment. The effect of these
deformities on HRQoL is not known. Finally, the inﬂuence
of comorbidities on HRQoL measures is not known.
Unfortunately, the rarity of this disorder makes evaluating
the inﬂuence of comorbidities difﬁcult.
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When presented with an acromegaly diagnosis, patients
typically have numerous questions concerning how this
disease will impact the rest of their life. Healthcare pro-
viders are in need of a tool to aid them in addressing these
questions. This tool needs to incorporate data on clinical
outcomes such as morbidity and mortality, HRQoL out-
comes, and economic outcomes including direct and indi-
rect costs. This tool would beneﬁt patients, healthcare
providers and policy makers evaluating treatment options
for this patient population. Major gaps in the existing lit-
erature surrounding health outcomes analyses in acro-
megaly include lack of integration of the impact that
comorbidities have on mortality, costs, HRQoL, and indi-
vidual patient productivity both before and after diagnosis
in situations of suboptimal disease control.
Figure 4 outlines a conceptual model for assessing
relevant health economic outcomes in acromegaly. For
example, the economic impact of reducing comorbidities
with strict biochemical control could be considered
(e.g., cardiac/hypertension, diabetes). One approach, in the
absence of acromegaly-speciﬁc data, would be to assess the
average treatment cost for each comorbidity from pub-
lished medical literature. For example, the cost of a ver-
tebral fracture is estimated at more than $3,800 in the ﬁrst
year [61], the annual/patient cost of cardiovascular disease
is more than $6,300/year [62], the cost of sleep apnea is
more than $2,200 [63], and the cost of arthropathy is more
than $3,100 annually [64]. These patients are at risk of
multiple comorbidities with suboptimal control, thus, the
additive economic impact of reduced comorbidities may
be signiﬁcant. In addition, shortening the latency period
between onset of disease, diagnosis, and treatment will
likely reduce the burden of high-cost complications that
may not be fully reversible such as diabetes, hypertension,
and facial deformity. There is a clear need to develop a full
assessment of the economic burden of acromegaly, as well
as the comparative effectiveness of available treatment
options using both economic modeling and retrospective
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Fig. 4 Conceptual model of the value of disease control in acromegaly
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123data analysis. This could be achieved by analyzing claims
data or undertaking extensive chart reviews.
Conclusions
Although the beneﬁts of acromegaly disease control are
well-known, there are many unanswered questions about
the beneﬁts of controlled compared with uncontrolled
disease regarding the dimensions of morbidities, HRQoL,
and costs. Beneﬁts of controlled disease, deﬁned as a
GH\2.5 lg/l and a normal age-adjusted IGF-1 level,
must clearly be deﬁned. The availability of a tool to aid
healthcare providers, policy makers, and patients in deter-
mining the effects of disease control on clinical, HRQoL,
and economic outcomes is needed. Future studies need to
evaluate clinical outcomes and also HRQoL and economic
outcomes achieved with controlled disease. Incorporation
of these data into a tool, which healthcare providers and
policy makers could use to evaluate treatment options and
determine the most effective treatment plans would be
invaluable for patients.
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